Гидреа (Hydroxycarbamide) is a systemic medication used for managing severe, chronic conditions in situations involving symptomatic discomfort and supporting symptom reduction. Its therapeutic scope is anchored in two primary domains: chronic hematology and oncology. The medication is commonly used to help patients manage complex symptomatic patterns related to specific disease pathology.

---

Controlling Abnormal Cell Growth in Blood Disorders

This treatment is commonly used for managing conditions characterized by pathological cell overproduction, such as Chronic Myeloid Leukemia (CML) and other Myeloproliferative Syndromes (e.g., Polycythemia Vera, Essential Thrombocythemia). Its use is relevant for controlling symptoms related to excessive cell activity—the stabilization and control of excessively high white blood cell or platelet counts—which may assist in moderating the course of the condition and may contribute to easing the risk of complications associated with cellular abundance.

---

Managing Pain Crises in Sickle Cell Disease

Гидреа is considered relevant for the long-term management of Sickle Cell Disease (SCD). Its use is aimed at managing the frequency and intensity of difficult, recurrent vaso-occlusive episodes (pain crises) and may assist in managing the risk of major complications. This stabilization may help in moderating the need for supportive blood transfusions and supports improved day-to-day comfort and management of disease stability, helping patients cope more steadily with symptom fluctuations.

---

“Applied across domains where additional symptomatic support is needed, Гидреа plays a role in managing symptoms that create noticeable physiological strain.”

Quick Fact: Relevant for Symptoms of Recurrent Pain

Primary Indications: Гидреа is commonly used for long-term conditions including Sickle Cell Disease, Chronic Myeloid Leukemia, and Myeloproliferative Syndromes like Polycythemia Vera and Essential Thrombocythemia.

Regulatory References

1. NIH MedlinePlus overview

Eligibility and Restrictions for Hydroxyurea (Hydrea / Гидреа)

Official regulatory guidelines strictly define the populations who can and cannot use hydroxyurea, primarily based on contraindications and specific risk factors.

Contraindications (Must Not Use)

• Hypersensitivity: Individuals with a known allergy or hypersensitivity to hydroxyurea or any component of the formulation.
• Severe Bone Marrow Depression: Use is prohibited if the patient exhibits marked myelosuppression, specifically leukopenia (WBC < 2,500/ mm^3) or thrombocytopenia (Platelet count < 100,000/ mm^3).
• Pregnancy and Lactation: The drug is contraindicated during pregnancy due to the risk of fetal harm. Breastfeeding must be discontinued as the drug is excreted in human milk.

Use with Restrictions or Caution

• Renal Impairment: Patients with significant renal function impairment (Creatinine Clearance < 60 mL/min) require mandatory dose reduction.
• Age: While approved for certain pediatric groups (e.g., in Sickle Cell Disease), safety and effectiveness are not established for all pediatric patients or indications. Older adults may require a lower dose due to increased sensitivity and potential decreased renal function.
• Contraception: Both male and female patients of reproductive potential must use effective contraception during and for specific periods after treatment.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Hydroxycarbamide (Гидреа) as classified in authoritative government regulatory sources.

---

Official Interaction Statements

Category	Documented Interaction Statement
Contraindicated Combinations	The co-administration of Live Vaccines is strictly prohibited due to the drug's immunosuppressive activity, which may result in severe or fatal infection. Additionally, the combination with the antiretroviral drugs Didanosine and Stavudine is associated with severe, potentially fatal toxicities (pancreatitis, hepatotoxicity, peripheral neuropathy), and should be avoided.
Pharmacodynamic Interactions	The myelosuppressive activity is potentiated when used concurrently with Radiotherapy or other Cytotoxic Chemotherapeutic Agents, increasing the risk of bone marrow depression. The development of severe cutaneous vasculitic toxicities (ulcerations and gangrene) has been documented primarily in patients with a history of or concurrent Interferon therapy.
Exposure Modification	Patients with Renal Impairment (creatinine clearance less than 60 mL/min) exhibit significantly increased plasma levels (AUC) of Hydroxycarbamide. This alteration in clearance requires specific exposure management. Prophylactic administration of Folic Acid is formally recommended to manage macrocytosis, which may otherwise mask a deficiency.
Food and Metabolism	Regulatory labels do not document clinically significant interactions mediated by major Cytochrome P450 enzymes or with food, and there are no mandatory timing separation rules for co-administered agents.

---

Connection to the official interaction profile: The regulatory interaction profile is primarily structured around avoiding or modifying dosage for pharmacodynamic interactions that lead to additive toxicities, alongside the mandatory requirement to adjust for altered pharmacokinetic clearance in renal impairment, as explicitly stated in the prescribing information.

Inhibiting DNA Precursor Synthesis via RNR Inactivation

This core mechanism involves the drug acting as a free radical scavenger to rapidly inactivate the enzyme Ribonucleotide Reductase (RNR). By inhibiting RNR, the drug severely depletes the cellular deoxyribonucleotide triphosphate (dNTP) pool, which are the essential molecular precursors for DNA. The resulting inability to synthesize new genetic material triggers S-phase arrest in the cell cycle. This selective molecular interference results in cytostatic and cytotoxic effects, causing a reduction in highly proliferative cell populations.

---

Secondary Modulation and Fetal Hemoglobin Induction

Separate from its cytotoxic action, the drug exerts a distinct molecular influence on the Nitric Oxide (NO) pathway. This modulation activates the pathway responsible for gamma globin gene expression in immature red blood cells. The consequence of this mechanism is the stimulation and production of Fetal Hemoglobin (HbF), a form of hemoglobin with distinct molecular properties. This pathway modulation alters the molecular composition of the blood, contributing to the full spectrum of observed physiological effects.

Hydroxycarbamide is an oral medication administered as a capsule, tablet, or solution. The prescribed quantity is a single daily dose, taken around the same time each day, and may be ingested with or without food.

Official Dosing Protocol

The total dose is determined by the patient’s actual or ideal body weight, whichever is less, and is typically expressed in milligrams per kilogram (mg/kg). For long-term conditions like Sickle Cell Disease (SCD), the initial dose is generally 15 mg/kg once daily. The dose is actively titrated (adjusted) over intervals of 8 to 12 weeks based strictly on the patient’s ongoing blood count monitoring. The maximum recommended daily dose for SCD is 35 mg/kg/day.

Administration Guidance and Adjustments

Capsules must be swallowed whole; tablets, if necessary, may be dispersed in a small amount of water for immediate ingestion. If a dose is missed, the standard procedure is to skip the missed dose and continue the regular schedule, without taking a double dose.

Specific dose adjustments are required for certain populations. For adults with renal impairment (Creatinine Clearance < 60 mL/min or End-Stage Renal Disease), the initial dose is typically reduced by 50%. Dosing for older adults may also begin at a lower regimen due to increased sensitivity. The treatment is considered a continuous, long-term therapy, where ongoing adherence to the prescribed frequency and dose modification schedule is central to its use protocol.

Гидреа: Recent Clinical Evidence

Research continues to examine the role of the compound, the active ingredient in Гидреа, across various conditions, primarily in hematological and neoplastic diseases. Clinical studies typically focus on efficacy, safety, and establishing optimal therapeutic protocols.

Studies in Hematology and Oncology

The compound is primarily investigated for its effects on cell proliferation and its role as a cytotoxic agent. Recent clinical evidence focuses on maintaining stable disease status and minimizing adverse effects across long-term treatment protocols.

• Sickle Cell Disease (SCD): Evidence from randomized controlled trials supports the use of the compound in reducing the frequency of vaso-occlusive crises and the need for blood transfusions in pediatric and adult patients with severe SCD. Long-term follow-up studies confirm the compound's effect on increasing fetal hemoglobin (HbF) levels, which is associated with improved clinical outcomes.
• Chronic Myeloid Leukemia (CML): Before the advent of tyrosine kinase inhibitors (TKIs), the compound was a standard treatment. Current research often evaluates its use in specific cases where TKI therapy is not feasible, focusing on its ability to control white blood cell counts and achieve cytoreduction.

---

Safety and Monitoring

Safety data remains crucial, given the compound’s non-specific cytotoxic properties. Key areas of focus in recent studies include:

Area of Concern	Study Observation
Myelosuppression	Requires regular monitoring of complete blood counts (CBC) as neutropenia and thrombocytopenia remain common, dose-limiting adverse effects.
Cutaneous Toxicity	Studies observe that skin changes, including leg ulcers and hyperpigmentation, are a recognized long-term risk and require management.

Discontinuing the compound is often necessary upon the development of severe myelosuppression or unmanageable toxicity.

Key Studies & References

1. Hydroxyurea therapy for children with sickle cell anemia: A systematic review and meta-analysis

Common questions about Гидреа (FAQ)

Q: Is Гидреа a long-term or short-term use medicine?

Official prescribing information indicates that Hydroxycarbamide (the active ingredient in Гидреа) is often used as a continuous, long-term therapy for disease control, particularly in chronic conditions.

Q: Can Гидреа cause hair loss or thinning?

Yes, official regulatory documents list alopecia (hair loss or thinning) as a documented side effect of the medicine. This is classified as an adverse reaction observed during treatment with Hydroxycarbamide.

Q: Can Гидреа cause digestive problems such as nausea or diarrhea?

Yes, according to the official product information, gastrointestinal issues such as nausea, vomiting, and diarrhea are classified as very common or common side effects. It is noted that these effects are frequently reported.

Q: Does Гидреа cause changes in nail color or structure?

Official drug labels note that changes to the skin and nails are a documented side effect. These changes can include hyperpigmentation (darkening or discoloration) of the nails and skin.

Q: Can Гидреа cause sleep problems?

Postmarketing surveillance reports have recorded cases of somnolence (drowsiness or sleepiness) and dizziness. These effects are classified as disorders of the nervous system and have been associated with the use of the drug.

Q: Is it true that the skin becomes more sensitive to the sun while taking Гидреа?

Yes, regulatory guidance advises patients to protect themselves from sun exposure. This is advised as a precaution because the medication may increase the risk of developing skin malignancies (cancers).

Q: How should one protect themselves from the sun during a course of Гидреа treatment?

Official instructions advise protection from the sun as a general measure. This guidance is provided to help mitigate the recognized risk of developing skin malignancies, such as skin cancer, associated with the medicine.

Q: What should I do if I miss a single dose of Гидреа?

Regulatory guidance states that if a dose is missed, the patient should skip the missed dose entirely and continue with the regular schedule. Patients are cautioned against taking a double dose to compensate for the missed one.

Q: Can Гидреа be used to treat other types of cancer besides those officially indicated?

Official indications state that Гидреа is only approved for treating chronic myeloid leukemia (CML). It is also indicated for specific squamous cell carcinomas of the head and neck (excluding the lip) when combined with radiation therapy.

Q: How extensive is the safety data on the long-term use of Гидреа (over 10 years)?

Official regulatory documents note that secondary malignancies (new cancers, including skin cancer and leukemia) have been reported in patients receiving long-term hydroxycarbamide therapy. This observation is a key component of the drug's long-term safety profile.

Q: How often does one need to visit a doctor for monitoring during Гидреа treatment?

Regulatory documents outline that a complete blood count should be monitored at least once per week at the start of treatment and regularly thereafter. This is done due to the risk of myelosuppression.

Q: Why does Гидреа sometimes cause anemia?

The drug works by suppressing the production of blood cells in the bone marrow (a side effect called myelosuppression). This action can lead to a reduction in the count of red blood cells, which results in anemia.

Q: What do official documents say about the possible effect of Гидреа on the liver?

Official prescribing information states that liver function should be monitored during treatment. Severe cases of hepatitis (liver inflammation) and/or cholestasis (impaired bile flow) have been reported as adverse reactions.

Q: Can Гидреа cause changes in the oral cavity (stomatitis)?

Yes. Stomatitis (inflammation of the mouth lining) and mouth ulcers are listed in regulatory documents as very common adverse effects associated with the medication.

Q: What precautions must be observed if the powder from a Гидреа capsule accidentally spills?

Due to the drug's cytotoxic nature, official guidelines advise handlers to avoid contact with the powder on the skin or mucous membranes and to avoid inhaling it. Official guidance emphasizes thorough hand washing after any contact with the capsules or their contents.

Q: Can Гидреа cause memory problems or dizziness while taking it?

Official safety reports include recorded instances of dizziness and deorientation. These are effects that impact the nervous system and have been associated with the drug.

Q: Why is Гидреа sometimes called Hydroxycarbamide?

Hydroxycarbamide is the active ingredient contained within the medication named Гидреа. Therefore, the names are often used interchangeably when referencing the drug substance.

How to Store and Dispose of Гидреа? (Hydroxycarbamide)

Official regulatory guidelines define strict protocols for the storage and disposal of Гидреа, a medicine classified as a cytotoxic and hazardous medicinal product.

Storage Requirements

Condition	Requirement
Temperature	Store at or below 25 C (Room temperature); do not refrigerate or freeze.
Container	Keep in the original container with the lid tightly closed to protect from moisture and light.
Safety	It is mandatory to keep out of the sight and reach of children.

Handling and Disposal Rules

Special precautions are required due to the cytotoxic nature of the capsules. Handlers should wear disposable gloves and wash their hands thoroughly before and after contact. Unused or expired Гидреа must not be disposed of via household trash or wastewater. Instead, discard the product according to authorized local hazardous waste or medicine take-back programs.